|
|
 |
|
Viewing report
|
|
|
|
Oral Cancer Therapies: Barriers and Pathways to Reimbursement
Datamonitor, Jan 2001
In the complex world of healthcare politics and economics, the choice of drug treatment is not always as straightforward as the product that is most efficacious and has the least number of side effects. In the case of oral cancer therapies, the economic aspects, which centers on who will pay for these new oral agents, are far-reaching. Oral Cancer Therapies: Barriers and Pathways to Reimbursement overviews the current status of reimbursement of cancer therapies within five major European markets, Japan and the US. With a focus on the US market, the issues and changes that are being brought about by the emergence of a new era of oral cancer therapies are discussed, to assess the likelihood that novel, oral cancer therapies will be granted reimbursable status.
Customers who bought this item also bought
Strategic Perspectives 2002: Colorectal Cancer Cost Analysis
Strategic Perspective 2001: Female Cancers - Optimizing Market Opportunities
Reimbursement in Europe, Japan and the US: The Impact of Cost Shifting on Pharmaceutical Strategies
Strategic Perspectives 2001: Breast Cancer Cost Analysis
Treatment Algorithms 2001: Venous Thromboembolism - Prophylaxis
Strategic Perspectives 2002: Endometriosis
Strategic Perspectives 2001: Cancer Patient Power - Partnering With a New Generation of Cancer Consumers
Treatment Algorithms 2002: Alzheimer's Disease - Aricept: the physicians choice
Strategic Perspectives 2001: Hormonal contraceptives
Treatment Algorithms 2002: Venous Thromboembolism Acute Therapy
Treatment Algorithms 2001 Breast Cancer: Herceptin Falling into Stride
Treatment Algorithms 2001: Lung Cancer
|
|
|
|
